Clinical trial · Interventional
Role of Activin A (ActA) in the Human Cancer Cachexia
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of the investigators study is to investigate the role of a hormone named Activin A (ActA) in the development of the skeletal muscle atrophy caused by cancer. According to the investigators hypothesis, ActA could be released by the tumor and activate a muscle atrophy gene program. To answer this question, the investigators plan first to compare circulating levels of ActA in cancer patients with and without cachexia. In a second step, the investigators would like to assess whether ActA circulating levels are predictive for the development of cachexia and short survival.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood tests and muscular biopsies | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- cachectic versus no cachectic patients
- description
- blood tests, muscular biopsies
- interventionNames
- Other: blood tests and muscular biopsies
Primary outcomes (1)
- measure
- Circulating Activin A level
- timeFrame
- 2 years
Secondary outcomes (6)
- measure
- Dietary assessment measured by SNAQ score and 3-Day intake
- timeFrame
- 2 years
- measure
- Body mass index
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18-year-old or older * Colorectal or lung cancer demonstrated by histology or cytology * New diagnosis or new recurrence * Expected survival more than 3 months * No previous history of other cancer in the last 5 years * No pregnancy or lactation * Signed informed consent Exclusion Criteria: * Non-caucasian * Major digestive malabsorption * Major depression * Artificial nutrition * Height doses of steroids (\>1 mg/kg hydrocortisone equivalent) * Hyperthyroidism * Other causes of malnutrition * Expected survival less than 3 months * Severely impaired walking * Anticoagulants or antiplatelet therapy * Disability or medical condition which might prevent the compliance to the protocol * Any conditions which may prevent the compliance to the protocol * Performance status ECOG \> ou = 4 * Participation to other clinical studies
References
Publications (1)
- DERIVEDLoumaye A, de Barsy M, Nachit M, Lause P, Frateur L, van Maanen A, Trefois P, Gruson D, Thissen JP. Role of Activin A and myostatin in human cancer cachexia. J Clin Endocrinol Metab. 2015 May;100(5):2030-8. doi: 10.1210/jc.2014-4318. Epub 2015 Mar 9. PMID 25751105